BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pan W, Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol 2018;50:289-99. [PMID: 28849345 DOI: 10.1007/s11255-017-1689-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Chang CH, Kor CT, Wu CL, Chiu PF, Li JR, Tsai CC, Chang TH, Chang CC. Increased chronic kidney disease development and progression in diabetic patients after appendectomy: a population-based cohort study. PeerJ 2018;6:e5019. [PMID: 29915707 DOI: 10.7717/peerj.5019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Li Y, Sun H, Du B, Xu H. Gut Microbiota Shifts in Pup Athymic BALB/c Mice: An Updated Identification in Nude Mice. Animals (Basel) 2019;9:E151. [PMID: 30965569 DOI: 10.3390/ani9040151] [Reference Citation Analysis]
3 Wang YF, Zheng LJ, Liu Y, Ye YB, Luo S, Lu GM, Gong D, Zhang LJ. The gut microbiota-inflammation-brain axis in end-stage renal disease: perspectives from default mode network. Theranostics 2019;9:8171-81. [PMID: 31754388 DOI: 10.7150/thno.35387] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
4 Zheng LJ, Lin L, Zhong J, Zhang Z, Ye YB, Zhang XY, Wang YF, Zhang H, Liu Y, Lu GM, Gong D, Zhang LJ. Gut dysbiosis-influence on amygdala-based functional activity in patients with end stage renal disease: a preliminary study. Brain Imaging Behav 2020;14:2731-44. [PMID: 32304020 DOI: 10.1007/s11682-019-00223-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Virzì GM, Breglia A, Ankawi G, Bolin C, de Cal M, Cianci V, Vescovo G, Ronco C. Plasma Lipopolysaccharide Concentrations in Cardiorenal Syndrome Type 1. Cardiorenal Med 2019;9:308-15. [PMID: 31238313 DOI: 10.1159/000500480] [Reference Citation Analysis]
6 Li Y, Yu T, Yan H, Li D, Yu T, Yuan T, Rahaman A, Ali S, Abbas F, Dian Z, Wu X, Baloch Z. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist 2020;13:1213-20. [PMID: 32431522 DOI: 10.2147/IDR.S210615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Juno JA, Eriksson EM. γδ T-cell responses during HIV infection and antiretroviral therapy. Clin Transl Immunology 2019;8:e01069. [PMID: 31321033 DOI: 10.1002/cti2.1069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
8 Zhu B, Shen J, Jiang R, Jin L, Zhan G, Liu J, Sha Q, Xu R, Miao L, Yang C. Abnormalities in gut microbiota and serum metabolites in hemodialysis patients with mild cognitive decline: a single-center observational study. Psychopharmacology (Berl) 2020;237:2739-52. [PMID: 32601991 DOI: 10.1007/s00213-020-05569-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Piqué N, Gómez-Guillén MDC, Montero MP. Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview. Int J Mol Sci 2018;19:E673. [PMID: 29495535 DOI: 10.3390/ijms19030673] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
10 Afkari R, Feizabadi MM, Ansari-Moghadam A, Safari T, Bokaeian M. Simultaneous use of oxalate-degrading bacteria and herbal extract to reduce the urinary oxalate in a rat model: A new strategy. Int Braz J Urol 2019;45:1249-59. [PMID: 31808414 DOI: 10.1590/S1677-5538.IBJU.2019.0167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 El-Deeb OS, Atef MM, Hafez YM. The interplay between microbiota-dependent metabolite trimethylamine N-oxide, Transforming growth factor β/SMAD signaling and inflammasome activation in chronic kidney disease patients: A new mechanistic perspective. J Cell Biochem 2019;120:14476-85. [PMID: 31002427 DOI: 10.1002/jcb.28707] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Yurinskaya MM, Krasnov GS, Kulikova DA, Zatsepina OG, Vinokurov MG, Chuvakova LN, Rezvykh AP, Funikov SY, Morozov AV, Evgen'ev MB. H2S counteracts proinflammatory effects of LPS through modulation of multiple pathways in human cells. Inflamm Res 2020;69:481-95. [PMID: 32157318 DOI: 10.1007/s00011-020-01329-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Baloglu I, Turkmen K. The importance of Oxalobacter formigenes and oxalic acid in the pathogenesis of chronic kidney disease. Int Urol Nephrol 2018;50:1189. [PMID: 29556902 DOI: 10.1007/s11255-018-1848-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Stavropoulou E, Kantartzi K, Tsigalou C, Konstantinidis T, Romanidou G, Voidarou C, Bezirtzoglou E. Focus on the Gut-Kidney Axis in Health and Disease.Front Med (Lausanne). 2020;7:620102. [PMID: 33553216 DOI: 10.3389/fmed.2020.620102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch 2020;472:303-20. [PMID: 32064574 DOI: 10.1007/s00424-020-02352-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
16 Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med 2020;132:495-505. [PMID: 32241215 DOI: 10.1080/00325481.2020.1744335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]